Racquel Bracken

Racquel Bracken is a General Partner at Venrock based in Palo Alto, California, where she specializes in healthcare and life sciences venture capital investments. She originally joined the prominent venture capital firm's healthcare investment team in 2016 before eventually being promoted to her current partnership role. Bracken focuses primarily on pharmaceutical and biotechnology investments, having executed at least two documented venture deals within the highly specialized medical sector. Her specific transaction history includes leading the Series B funding round for Cyteir, an oncology startup developing novel treatments targeting DNA damage. Additionally, she provides strategic oversight and corporate governance by currently serving on the board of directors for the biopharmaceutical company MBrace. Her ongoing professional focus remains centered on identifying, funding, and scaling early-stage therapeutics and biotechnology companies with a particular emphasis on advanced oncology solutions.